Opinion

Video

Beamion LUNG-1: Zongertinib in Advanced HER2-Mutated NSCLC

Author(s):

Edgardo S. Santos, MD, FACP, FCCPMartin Dietrich, MD, PhD

The panel offers comprehensive insights on the Beamion LUNG-1 clinical trial, which is investigating zongertinib in patients with advanced HER2-mutated non–small cell lung cancer.

Related Videos
Idoroenyi Amanam, MD
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
Andrea Wolf, MD, MPH
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Nagashree Seetharamu, MD, MBBS
Shirish M. Gadgeel, MD
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie
Related Content
Charnita Zeigler-Johnson, PhD, MPH
Published: September 20th 2024 | Updated: September 20th 2024

Fox Chase Cancer Center Researchers Examine Perceptions of Smoking Stigma Among African American/Black Populations

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Alexander Spira, MD, PhD, FACP
September 18th 2024

Experts Highlight Top Findings From the 2024 IASLC World Conference on Lung Cancer

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Marjorie Green, MD
September 17th 2024

Patritumab Deruxtecan Meets PFS End Point in Pretreated EGFR-Mutant NSCLC

Lung cancer
September 16th 2024

Several IO Combos Miss Efficacy Target in NSCLC, But Clinical Benefit Seen With 2 Combos